Pamatolol: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|Overview of the beta-blocker Pamatolol}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Pamatolol.svg | |||
| image_size = 200px | |||
| image_alt = | |||
| image_caption = Chemical structure of Pamatolol | |||
}} | |||
'''Pamatolol''' is a [[beta-adrenergic blocking agent]] (beta-blocker) used in the management of various cardiovascular conditions. It is known for its ability to reduce [[heart rate]], [[blood pressure]], and myocardial oxygen demand by blocking the action of [[epinephrine]] and [[norepinephrine]] on beta-adrenergic receptors. | |||
Pamatolol | |||
== | ==Pharmacology== | ||
Pamatolol is | Pamatolol is a non-selective beta-blocker, meaning it inhibits both [[beta-1 adrenergic receptor|beta-1]] and [[beta-2 adrenergic receptor|beta-2]] adrenergic receptors. This action results in decreased cardiac output and peripheral resistance, which contributes to its antihypertensive effects. | ||
== | ===Mechanism of Action=== | ||
Pamatolol works by competitively blocking the beta-adrenergic receptors in the heart and vascular smooth muscle. This blockade prevents the usual sympathetic nervous system response, leading to a decrease in heart rate and contractility, as well as vasodilation. | |||
== | ==Clinical Uses== | ||
Pamatolol is primarily used in the treatment of [[hypertension]], [[angina pectoris]], and certain types of [[arrhythmia]]. It may also be used in the management of [[myocardial infarction]] to reduce mortality and improve outcomes. | |||
==Side Effects== | |||
Common side effects of Pamatolol include [[bradycardia]], [[fatigue]], [[dizziness]], and [[gastrointestinal disturbances]]. As with other beta-blockers, it may exacerbate symptoms of [[asthma]] and [[chronic obstructive pulmonary disease]] (COPD) due to its non-selective action. | |||
== Contraindications == | ==Contraindications== | ||
Pamatolol is contraindicated in | Pamatolol is contraindicated in patients with [[asthma]], [[severe bradycardia]], [[heart block]], and [[cardiogenic shock]]. Caution is advised in patients with [[diabetes mellitus]] as it may mask hypoglycemic symptoms. | ||
== | ==Related pages== | ||
* [[Beta blocker]] | |||
* [[Hypertension]] | |||
* [[Angina pectoris]] | |||
* [[Arrhythmia]] | |||
[[Category:Beta blockers]] | [[Category:Beta blockers]] | ||
[[Category:Antihypertensive agents]] | |||
[[Category:Antihypertensive | |||
Latest revision as of 04:02, 13 February 2025
Overview of the beta-blocker Pamatolol
Pamatolol is a beta-adrenergic blocking agent (beta-blocker) used in the management of various cardiovascular conditions. It is known for its ability to reduce heart rate, blood pressure, and myocardial oxygen demand by blocking the action of epinephrine and norepinephrine on beta-adrenergic receptors.
Pharmacology[edit]
Pamatolol is a non-selective beta-blocker, meaning it inhibits both beta-1 and beta-2 adrenergic receptors. This action results in decreased cardiac output and peripheral resistance, which contributes to its antihypertensive effects.
Mechanism of Action[edit]
Pamatolol works by competitively blocking the beta-adrenergic receptors in the heart and vascular smooth muscle. This blockade prevents the usual sympathetic nervous system response, leading to a decrease in heart rate and contractility, as well as vasodilation.
Clinical Uses[edit]
Pamatolol is primarily used in the treatment of hypertension, angina pectoris, and certain types of arrhythmia. It may also be used in the management of myocardial infarction to reduce mortality and improve outcomes.
Side Effects[edit]
Common side effects of Pamatolol include bradycardia, fatigue, dizziness, and gastrointestinal disturbances. As with other beta-blockers, it may exacerbate symptoms of asthma and chronic obstructive pulmonary disease (COPD) due to its non-selective action.
Contraindications[edit]
Pamatolol is contraindicated in patients with asthma, severe bradycardia, heart block, and cardiogenic shock. Caution is advised in patients with diabetes mellitus as it may mask hypoglycemic symptoms.
